EMA committee recommends approval of Yuviwel for achondroplasia in children
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Yuviwel (navepegritide), a once-weekly growth therapy for children with achondroplasia. A final decision from the European Commission is expected in Q4 2026.
